Loading market observation…
Loading research…
Model estimates are informational, not investment advice. They are uncertain, may be wrong, and do not guarantee future prices.
Latest observed price
$44.90
Session change unavailableStatus checked Oct 25, 2026, 12:37 AM · America/New_York
Observed Sep 21, 2026, 8:00 PM UTC · Last available price
The latest observed price above is market data. Forecast starting prices are issuance-frozen values and are labelled separately in Model Forecast below.
Review the dated model forecast and five-factor Scorecard for IONS. Each has its own availability and reference date; a score is a relative comparison, not a price prediction.
Lower Estimate (P10)
$21.22
-52.8%
Median Estimate (P50)
$54.76
+22.0% from starting price
Upper Estimate (P90)
$139.52
+210.7%
The estimate uses its dated starting price. It does not predict returns from today’s quote.
View forecast details, dates and available rangesLoading research…
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Loading research…
Risk / safety methodology: Safety describes recent price swings and distance from a recent high alongside cash flow and profitability. It is not a credit rating or a promise of protection from loss.
Multi-factor scoring at a glance
Individual factor readings · Shading shows available dimensions only. Overall requires all five scores and a comparable peer group.
A combined view of Value, Quality, Growth, Safety and Momentum. Review the factor breakdown alongside the total.
Scores and key insights for each dimension
How its fundamental growth measures compare.
How its valuation measures compare with the group.
How its profitability and operating quality compare.
How its price swings, distance from a recent high, cash flow and profitability compare.
How its recent price-trend measures compare.
All scores in this Scorecard describe relative characteristics as of the shown date, using historical market data and reported company information; higher scores on the 0–100 scale indicate more favorable characteristics in the relevant comparison group, and none forecasts future performance.
Higher scores indicate higher relative readings.
Upgrade to Pro to explore this analysis.
Scores are relative comparisons, not absolute grades: companies with different coverage may be scored on different inputs. Peer positions and input coverage can differ by factor; use the displayed comparison group and date when comparing readings. An 80 is not an 80% chance of a price rise. These scores are not price forecasts or recommendations.
The rank with complete inputs compares only companies with every input for that factor, using the issued scores. Equal partial coverage percentages do not establish matching inputs. Current stockwide snapshots use matching input groups; older snapshots may use a smaller fixed group. Scores do not separately adjust for industry or company size. Growth readings do not establish multi-year persistence or separate share-count effects from EPS growth. Scores are independent of the selected forecast horizon.
Latest update · 2026-09-21
View Plans to read the previous successful update.
Previous update means the last successfully published update, including across weekends and market holidays. The Analysis tab keeps the information used in its latest report.
Open a ready-made screen, review its filters and adapt it to your questions.
Upgrade to Plus or Pro to explore this analysis.
Upgrade to Plus or Pro to explore this analysis.
Upgrade to Plus or Pro to explore this analysis.
A comparison appears after a previous update is available.
Upgrade to Plus or Pro to explore this analysis.
Start with profit, cash generation and financial flexibility. Scores describe relative characteristics and do not predict returns.
Market observations, financial reporting periods and report dates can differ. Each measure shows its own period.
Compare company metrics only when their currency, observation date and reporting periods agree. Similar companies are starting points for research, not substitutes for each other.
Upgrade to Plus or Pro to explore this analysis.
Economic observations provide background. Observation periods and release dates can differ; these readings do not establish a company-specific effect.
Unavailable
Reported ownership and transaction amounts are disclosure observations, not investment instructions. Filing dates can lag the transaction date.
Unavailable
New filing entries since the previous update. An entry does not establish a change in the document's contents.
Keep your own questions and observations with this company.
Sign in to save a noteExplore related companies in our coverage. Open a stock for its full forecast and Scorecard.
BBIO
Latest observed price
$66.58
Observed
Sep 21, 2026
12-month forecast
Median (P50)
$77.33
+16.1%
From $66.58 starting price
Target Sep 21, 2027
Overall Score
UnavailableForecast basis Sep 21, 2026
Score date —
BMRN
Latest observed price
$64.06
Observed
Sep 21, 2026
12-month forecast
Median (P50)
$68.31
+6.6%
From $64.06 starting price
Target Sep 21, 2027
Overall Score
ModerateForecast basis Sep 21, 2026
Score date Sep 22, 2026
EXEL
Latest observed price
$57.22
Observed
Sep 21, 2026
12-month forecast
Median (P50)
—
Overall Score
StrongForecast basis —
Score date Sep 22, 2026
MDGL
Latest observed price
$521.96
Observed
Sep 21, 2026
12-month forecast
Median (P50)
$597.42
+14.5%
From $521.96 starting price
Target Sep 21, 2027
Overall Score
UnavailableForecast basis Sep 21, 2026
Score date —
12-month forecasts show model median estimates (P50), with changes from each forecast’s starting price. Headline scores describe dated company characteristics; they do not predict future performance.
